skip navigation, go to content
Neuroprotection Exploratory Trials in Parkinson's Disease: NET-PD National Institute of Neurological Disorders and Stroke logo
National Institutes of Health
NET-PD Home
[What is the NET-PD Study?]
[Who is sponsoring NET-PD?]
[Enrolling now: FS-Zone]
[What other drugs are being studied?]
[Study publications]
[Privacy and confidentiality]
[En Espaņol]
[For more information, call toll free 1-800-352-9424 email  info@parkinsontrial.org or visit clinicaltrials.gov.] info@partkinsontrial.org clinicaltrials.gov Learn more about NET-PD clinical trials for Parkinson's Disease
[What drugs are being studied?]

The NINDS NET-PD investigators are completing a study (called LS-1) to determine if a highly purified form of creatine can slow disease progression in people with Parkinson's disease. In this study, 1740 subjects have been assigned to take either 5 grams of creatine or a matching placebo (an inactive substance) twice per day for at least 5 years. Researchers will evaluate whether Parkinson's disease symptoms worsen at a slower rate in the subjects who are taking creatine compared to those taking placebo. The LS-1 study is no longer enrolling new subjects. At this time, it is in the process of following the enrolled subjects for the intended five year treatment period.


NET-PD Home | What is the NET-PD Study? | Who is sponsoring NET-PD? | Enrolling now: FS-Zone
What other drugs are being studied? | Study publications | Privacy and confidentiality | En Espaņol
NINDS Home | Download Adobe Reader

U.S. Department of Health and Human Services logo     National Institutes of Health logo     USA.gov logo

NIH...Turning Discovery Into Health®